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Background: A great deal of evidence has shown that iron is an important component in cognitive, sensorimotor,
and social-emotional development and functioning, because the development of central nervous system processes
is highly dependent on iron-containing enzymes and proteins. Deficiency of iron in early life may increase the risk
of psychiatric morbidity.
Methods: Utilizing the National Health Insurance Database from 1996 to 2008, children and adolescents with a
diagnosis of IDA were identified and compared with age and gender-matched controls (1:4) in an investigation of
the increased risk of psychiatric disorders.
Results: A total of 2957 patients with IDA, with an increased risk of unipolar depressive disorder (OR = 2.34, 95% CI =
1.58 ~ 3.46), bipolar disorder (OR = 5.78, 95% CI = 2.23 ~ 15.05), anxiety disorder (OR = 2.17, 95% CI = 1.49 ~ 3.16), autism
spectrum disorder (OR = 3.08, 95% CI = 1.79 ~ 5.28), attention deficit hyperactivity disorder (OR = 1.67, 95% CI = 1.29 ~ 2.17),
tic disorder (OR = 1.70, 95% CI = 1.03 ~ 2.78), developmental delay (OR = 2.45, 95% CI = 2.00 ~ 3.00), and mental retardation
(OR = 2.70, 95% CI = 2.00 ~ 3.65), were identified. A gender effect was noted, in that only female patients with IDA had an
increased OR of bipolar disorder (OR = 5.56, 95% CI = 1.98 ~ 15.70) and tic disorder (OR = 2.95, 95% CI = 1.27 ~ 6.86).
Conclusion: Iron deficiency increased the risk of psychiatric disorders, including mood disorders, autism spectrum
disorder, attention deficit hyperactivity disorder, and developmental disorders. Further study is required to clarify the
mechanism in the association between IDA and psychiatric disorder.
Keywords: Iron deficiency anemia, Psychiatric disorders, ComorbidityBackground
According to the World Health Organization, iron defi-
ciency (ID) is the most prevalent nutritional deficiency.
A 30% prevalence of iron deficiency anemia (IDA), at a
minimum, has been noted among children, adolescents,
and women in non-industrialized countries, and ID is
also the most prevalent nutritional deficiency in industri-
alized countries [1-4]. ID, defined by two or more abnor-
mal measurements (serum ferritin, transferrin saturation,* Correspondence: ymbi@mail2000.com.tw
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reproduction in any medium, provided the orerythrocyte protoporphyrin), is insidious and uneasily de-
tected by patients themselves and may not develop sig-
nificant clinical symptoms [1-4]. IDA is characterized by a
defect in hemoglobin synthesis owing to significant ID,
resulting in the reduced capacity of the red blood cells to
deliver oxygen to body cells and tissues, and many clinical
symptoms, such as pale conjunctiva, shortness of breath,
dizziness, and lethargy [1-4]. The main risk factors for
IDA and ID include a low intake of iron, poor ab-
sorption of iron from diets, chronic loss of iron (i.e.,
ulcer, metrorrhagia), and some specific periods of life
when iron requirements are especially high, such as
growth and pregnancy [1-4].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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globin, and many enzymes in cellular metabolism and
DNA replication and repair. It also plays a crucial role in
the development of the central neurological system
[5-8], autoimmune system [9-11], endocrine system
[12-15], and cardiovascular system [16,17]. In the devel-
opment of the brain, iron accounted for the myelination
of white matter [18,19] and the development and func-
tioning of the different neurotransmitter systems, includ-
ing the dopamine, norepinephrine, and serotonin
systems [20-22]. In vivo microdialysis studies using post-
weaning iron-deficient rats and mice demonstrated that
they exhibited deficits in intracellular dopamine concen-
trations and in the density of dopamine and dopamine
transporter receptors, with variable amounts of loss by
brain region [23-26]. Anderson et al. showed that de-
creased iron significantly reduced extracellular concen-
trations of norepinephrine in the caudate putamen, and
altered levels of norepinephrine due to reduced iron
levels may be the result of changes in the expression of
norepinephrine transport and norepinephrine receptor
proteins in the locus ceruleus and basal ganglia [27,28].
A reduction in serotonin transporter binding was noted
in the nucleus accumbens and olfactory tubercle in iron-
deficient rats [21], and the serotonin concentration in
the brain was significantly correlated with the non-heme
iron level [29].
In summary, IDA and ID were significantly associated
with an alteration of monoamine neurotransmitters and
the abnormal myelination of white matter, and is prob-
ably related to childhood/adolescence-onset psychiatric
disorders. There is well documented evidence in the lit-
erature that IDA has a significant influence on cognitive
development, intelligence, and developmental delay
[30,31]. However, the association between IDA and other
childhood/adolescence-onset psychiatric disorders is still
limited. Some clinical studies supposed that brain ID in-
volved in the pathophysiology of attention deficit hyper-
activity disorder (ADHD) [32] and ferritin level was
related to behavioral symptoms in ADHD patients [33].
But, Millichap et al. disclosed no significant difference in
severity of ADHD symptoms between children with
ADHD who had the lower serum ferritin levels (<20 ng/
mL) and those who had the higher levels (>60 ng/mL)
[34]. And a high prevalence, up to 30%, of IDA was ob-
served in children with autism spectrum disorder (ASD),
which was supposed to potentially compromise their
communication and behavior [35,36]. As for schizophre-
nia, bipolar disorder (BD), unipolar depressive disorder,
and anxiety disorder, the data are quite limited. This
study, using a nationwide population-based insurance
database with a case–control method and the largest
sample size, attempted to clarify the association between
IDA and various psychiatric disorders among childrenand adolescents with IDA. We hypothesized that chil-
dren and adolescents with ADHD exhibited the higher
risk of having a psychiatric disorder.
Methods
Data source
The National Health Insurance (NHI) program was
implemented in Taiwan in 1995. Since 2001, Taiwan’s
NHI has covered 96.9% of all 23,000,000 residents of
Taiwan. The completeness and accuracy of the NHI
claims database has been audited by the Department of
Health and the Bureau of NHI. The database provides
demographic and medical information on insured resi-
dents, including age, gender, prescription drugs, pre-
scription date, and the prescription and diagnosis using
the International Classification of Diseases, 9th Revision,
Clinical Modification (ICD-9-CM). The NHI Research
Database (NHIRD) has been used extensively in many
epidemiologic studies in Taiwan [37-39]. Our study was
approved by Institutional Review Board of Taipei Vet-
erans General Hospital (2012-04-012BC).
Inclusion criteria for IDA and psychiatric disorders
In this study, 1,000,000 subjects, approximately 4.3% of the
population of Taiwan, were randomly selected from the
NHIRD. The study comprised all children and adolescents
(aged younger than 18) who were identified by the diagnos-
tic code of “iron deficiency anemia” (ICD-9-CM: 280) be-
tween January 1, 1996 and December 31, 2008. Diagnosis
was given by board-certificated pediatricians and physi-
cians. Coexistent psychiatric disorders were investigated by
specific diagnostic codes, and included schizophrenia (ICD-
9-CM code: 295), BD (ICD-9-CM code: 296 except 296.2
and 296.3), unipolar depressive disorder (ICD-9-CM codes:
296.2, 296.3, 300.4, and 311 for major depressive disorder,
dysthymic disorder, depressive disorder, not specified),
obsessive-compulsive disorder (OCD) (ICD-9-CM code:
300.3), anxiety disorder (ICD-9-CM code: 300 except 300.3
and 300.4), ASD (ICD-9-CM code: 299), ADHD (ICD-9-
CM code: 314), tic disorder (ICD-9-CM: 307.2), delayed de-
velopment (ICD-9-CM code: 315), and mental retardation
(ICD-9-CM code: 317 ~ 319). Finally, gastrointestinal ulcer
(ICD-9-CM code: 531 ~ 534), metrorrhagia (ICD-9-CM
code: 626.2 and 626.6), and premenopausal menorrhea
(ICD-9-CM code: 627.0) were used as covariates. All psy-
chiatric diagnoses were given by board-certified psychia-
trists. The diagnoses of delayed development and mental
retardation were given by board-certificated psychiatrists,
rehabilitation specialists, and pediatricians.
Control group
The age and gender-matched control group (4 for every
patient in the study cohort) was randomly identified
from subjects who had no major physical illnesses,
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tological disease (ICD-9-CM code: 280 ~ 289), chronic
liver disease (ICD-9-CM code: 570 ~ 573), chronic renal
disease (ICD-9-CM code: 585, 586), chronic inflamma-
tory disease (ICD-9-CM code: 710 for diffuse diseases
of connective tissue, 714 for rheumatoid arthritis and
other inflammatory polyarthropathies, 720 for ankylos-
ing spondylitis and other inflammatory spondylopathies,
555 for Crohn’s disease, 556 for idiopathic proctocolitis),
chronic infectious disease (ICD-9-CM code: 010 ~ 018
for tuberculosis, 042 ~ 044 for human immunodeficien-
cy virus, 070 for viral hepatitis, 090 ~ 099 for syphilis,
390 ~ 392 for rheumatic fever, 730 for osteomyelitis),
endocrine disease (ICD-9-CM code: 240 ~ 246 for thy-
roid disease, 249 ~ 250 for diabetes mellitus, 252 for para-
thyroid disease, 253 for pituitary disease, 255 for adrenal
gland disease), and nutritional deficiency (ICD-9-CM
code: 260 ~ 269).
Statistical analysis
For between-group comparisons, the independent t test
was used for continuous variables and Pearson's X2 test
or Fisher's exact test was applied for nominal variables,
where appropriate. Multiple logistic regressions were
performed to calculate the OR with 95% confidence in-
tervals (CI) after adjusting for ulcer, metrorrhagia, and
premenopausal menorrhea (because ulcer and metror-
rhagia were two important risks causing IDA of children
and adolescents). A two-tailed P-value of less than 0.05
was considered statistically significant. All data process-
ing and statistical analyses were performed with Statis-
tical Package for Social Science (SPSS) version 17
software (SPSS Inc) and Statistical Analysis Software
(SAS) version 9.1 (SAS Institute, Cary, NC).Table 1 Characteristics of patients with iron deficiency anemi
Characteristics of IDA Male
No. 1060
Age (years) 7.46 ± 5.68
Associated diseases, N (%)
Schizophrenia 2 (0.2)
Unipolar depressive disorder 12 (1.1)
Bipolar disorder 2 (0.2)
OCD 1 (0.1)
Anxiety disorder 21 (2.0)
ASD 17 (1.6)
ADHD 64 (6.0)
Tic disorder 14 (1.3)
Delayed development 90 (8.5)
Mental retardation 47 (4.4)
OCD obsessive-compulsive disorder, ASD autistic spectrum disorder, ADHD attentionResults
Demographic characteristics of the IDA patients and
control group
A total of 2957 children and adolescents (1060 males
and 1897 females) were identified as having IDA from
the 1,000,000-person sample population between Janu-
ary 1, 1996 and December 31, 2008. The mean age was
10.59 ± 6.02 years and male patients were significantly
younger than the females (7.46 ± 5.68 vs. 12.34 ± 5.46,
p < 0.001). Male IDA patients exhibited a significantly
higher prevalence of ASD (1.6% vs. 0.4%, p < 0.001),
ADHD (6.0% vs. 1.1%, p < 0.001), tic disorder (1.3% vs.
0.5%, p = 0.027), delayed development (8.5% vs. 3.4%,
p < 0.001), and mental retardation (4.4% vs. 1.5%, p <
0.001) than the females (Table 1). In comparing the dif-
ference between the IDA patients and the control group,
the IDA patients had a significantly increased prevalence
of psychiatric comorbidities, including unipolar depres-
sive disorder (1.6% vs. 0.6%, p < 0.001), BD (0.4% vs.
0.1%, p < 0.001), anxiety disorder (1.5% vs. 0.7%, p <
0.001), ASD (0.8% vs. 0.3%, p < 0.001), ADHD (2.8% vs.
1.8%, p < 0.001), tic disorder (0.8% vs. 0.5%, p = 0.044),
delayed development (5.2% vs. 2.4%, p < 0.001), and
mental retardation (2.5% vs. 1.0%, p < 0.001) (Table 2).
Odds ratio of psychiatric disorders
In examining the association between IDA and child-
hood/adolescence-onset psychiatric disorders, multiple
logistic regression analysis was used to evaluate the OR
of psychiatric comorbidity among those with IDA, after
adjusting for age, gender, ulcer, metrorrhagia, and
premenopausal menorrhea. Patients with IDA were
prone to having a significantly higher chance of being
associated with unipolar depressive disorder (OR = 2.34,a (IDA)
Female p-value All
1897
12.34 ± 5.46 <0.001 10.59 ± 6.02
6 (0.3) 0.719 8 (0.3)
36 (1.9) 0.104 48 (1.6)
11 (0.6) 0.154 13 (0.4)
3 (0.2) >0.999 4 (0.1)
24 (1.3) 0.158 45 (1.5)
7 (0.4) 0.001 24 (0.8)
20 (1.1) <0.001 84 (2.8)
9 (0.5) 0.027 23 (0.8)
64 (3.4) <0.001 154 (5.2)
28 (1.5) <0.001 75 (2.5)
-deficit hyperactivity disorder.
Table 2 Characteristics of patients with iron deficiency
anemia (IDA) and control subjects
Characteristics IDA Control p-value
No. 2957 11828
Age (years) 10.59 ± 6.02 10.59 ± 6.02
Sex, N (%)
Male 1060 (35.8) 4240 (35.8)
Female 1897 (64.2) 7588 (64.2)
Associated diseases, N (%)
Schizophrenia 8 (0.3) 14 (0.1) 0.063
Unipolar depressive disorder 48 (1.6) 66 (0.6) <0.001
Bipolar disorder 13 (0.4) 7 (0.1) <0.001
OCD 4 (0.1) 8 (0.1) 0.274
Anxiety disorder 45 (1.5) 80 (0.7) <0.001
ASD 24 (0.8) 32 (0.3) <0.001
ADHD 84 (2.8) 207 (1.8) <0.001
Tic disorder 23 (0.8) 56 (0.5) 0.044
Delayed development 154 (5.2) 278 (2.4) <0.001
Mental retardation 75 (2.5) 114 (1.0) <0.001
IDA iron deficiency anemia, OCD obsessive-compulsive disorder, ASD autistic
spectrum disorder, ADHD attention-deficit and hyperactivity disorder.
Chen et al. BMC Psychiatry 2013, 13:161 Page 4 of 8
http://www.biomedcentral.com/1471-244X/13/16195% CI = 1.59 ~ 3.46), BD (OR = 5.80, 95% CI = 2.24 ~
15.05), anxiety disorder (OR = 2.17, 95% CI = 1.49 ~
3.16), ASD (OR = 3.08, 95% CI = 1.79 ~ 5.28), ADHD
(OR = 1.67, 95% CI = 1.29 ~ 2.17), tic disorder (OR =
1.70, 95% CI = 1.03 ~ 2.78), delayed development (OR =
2.45, 95% CI = 2.00 ~ 3.00), and mental retardation
(OR = 2.70, 95% CI = 2.00 ~ 3.65) (Table 3). We also in-
vestigated the gender effect on IDA and associated psy-
chiatric comorbidities (Table 3). A significantly increased
risk of unipolar depressive disorder (OR = 2.36, 95%
CI = 1.10 ~ 5.10), anxiety disorder (OR = 1.73, 95% CI =
1.02 ~ 2.94), ASD (OR = 2.66, 95% CI = 1.41 ~ 5.00),
ADHD (OR = 1.51, 95% CI = 1.12 ~ 2.04), delayedTable 3 Association between iron deficiency anemia (IDA) an
OR (95% CI) Male Female
Schizophrenia 2.20 (0.40, 12.02) 2.15 (0.76, 6.10)
Unipolar depressive disorder 2.36 (1.10, 5.10) 2.37 (1.51, 3.73)
Bipolar disorder 8.80 (0.80, 97.14) 5.56 (1.98, 15.70)
OCD 0.78 (0.08, 7.48) 3.07 (0.67, 14.13)
Anxiety disorder 1.73 (1.02, 2.94) 2.69 (1.57, 4.62)
ASD 2.66 (1.41, 5.00) 4.07(1.39, 11.90)
ADHD 1.51 (1.12, 2.04) 2.00 (1.14, 3.49)
Tic disorder 1.23 (0.66, 2.30) 2.95 (1.27, 6.86)
Delay in development 1.95 (1.50, 2.53) 3.48 (2.48, 4.88)
Mental retardation 3.09 (2.08, 4.61) 2.13 (1.34, 3.40)
OCD obsessive-compulsive disorder, ASD autistic spectrum disorder, ADHD attention
Bold type denotes statistically significant odds ratio (OR).development (OR = 1.95, 95% CI = 1.50 ~ 2.53), and
mental retardation (OR = 3.09, 95% CI = 2.08 ~ 4.61)
were observed in male IDA patients in comparison with
females, while a significantly higher risk of unipolar de-
pressive disorder (OR = 2.37, 95% CI = 1.51 ~ 3.73), BD
(OR = 5.56, 95% CI = 1.98 ~ 15.70), anxiety disorder
(OR = 2.69, 95% CI = 1.57 ~ 4.62), ASD (OR = 4.07, 95%
CI = 1.39 ~ 11.90), ADHD (OR = 2.00, 95% CI = 1.14 ~
3.49), tic disorder (OR = 2.95, 95% CI = 1.27 ~ 6.86), de-
layed development (OR = 3.48, 95% CI = 2.48 ~ 4.88),
and mental retardation (OR = 2.13, 95% CI = 1.34 ~ 3.40)
were noted in female IDA patients compared with males
(Table 3).
Odds ratio of psychiatric disorder stratified by age
We performed adjusted multiple logistic regression strati-
fied by age to elucidate the association between IDA and
various psychiatric comorbidities, focusing on children
and adolescents with IDA, respectively (Table 3). Children
were defined as those younger than 13 and adolescents as
those aged 13 ~ 18. Children with IDA exhibited a signifi-
cantly higher risk of ASD (OR = 3.00, 95% CI = 1.70 ~
5.27), ADHD (OR = 1.50, 95% CI = 1.12 ~ 1.99), delayed
development (OR = 2.23, 95% CI = 1.79 ~ 2.78), and men-
tal retardation (OR = 3.01, 95% CI = 2.09 ~ 4.32) (Table 3).
Adolescents with IDA were significantly associated with
unipolar depressive disorder (OR = 2.89, 95% CI = 1.84 ~
4.54), BD (OR = 6.05, 95% CI = 1.97 ~ 18.58), anxiety dis-
order (OR = 3.71, 95% CI = 2.16 ~ 6.37), ADHD (OR =
2.54, 95% CI = 1.31 ~ 4.95), tic disorder (OR = 3.73, 95%
CI = 1.12 ~ 12.48), delayed development (OR = 3.88, 95%
CI = 2.17 ~ 6.95), and mental retardation (OR = 2.08, 95%
CI = 1.22 ~ 3.57) (Table 3).
Discussion
The results of our clinical epidemiological study sup-
ported previous findings that IDA is significantlyd psychiatric disorders
Children (Age <13) Adolescent (Age≧13) All
4.35 (0.27, 69.56) 2.04 (0.79, 5.28) 2.11 (0.86, 5.15)
1.33 (0.58, 3.04) 2.89 (1.84, 4.54) 2.34 (1.59, 3.46)
5.20 (0.83, 32.71) 6.05 (1.97, 18.58) 5.80 (2.24, 15.05)
– 3.01 (0.77, 11.77) 1.87 (0.55, 6.40)
1.29 (0.74, 2.26) 3.71 (2.16, 6.37) 2.17 (1.49, 3.16)
3.00 (1.70, 5.27) 2.55 (0.40, 16.24) 3.08 (1.79, 5.28)
1.50 (1.12, 1.99) 2.54 (1.31, 4.95) 1.67 (1.29, 2.17)
1.41 (0.81, 2.43) 3.73 (1.12, 12.48) 1.70 (1.03, 2.78)
2.23 (1.79, 2.78) 3.88 (2.17, 6.95) 2.45 (2.00, 3.00)
3.01 (2.09, 4.32) 2.08 (1.22, 3.57) 2.70 (2.00, 3.65)
-deficit hyperactivity disorder.
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disorder, BD, anxiety disorder, ASD, ADHD, delayed de-
velopment, and mental retardation among children and
adolescents.
Mental retardation and delayed development
Our results showed a higher prevalence of mental re-
tardation and delayed development among subjects with
IDA, which was consistent with previous findings
[31,40,41]. Beltrán-Navarro et al. used the Bayley Scales
of Infant Development, preschool language scales and an
environmental sound perception task to assess the effect
of IDA on multifaceted development in infancy (at 6 and
14 to 18 months) and showed that infants with chronic
IDA did show significantly lower scores on language, en-
vironmental sound perception, and motor measures,
when compared with infants with a normal iron nutri-
tional status [42]. Studying the long-term developmental
outcome of infants with IDA, Lozoff et al. found lower
scores on tests of mental (i.e., intelligence) and motor
functioning at age of 5 and 12 among those with IDA in
infancy [31,40]. Furthermore, IDA can impair cognitive
performance at all stages of life. Halterman et al. assessed
5398 children and adolescents aged 6 to 16 and demon-
strated that subjects with IDA had more than twice the
risk of scoring below average in scholastic achievement
than the children with a normal iron status [43].
Attention deficit hyperactivity disorder (ADHD)
Previous studies on iron and the pathophysiology of
ADHD have had inconsistent results. In a small cohort
study comprising 52 ADHD children, Oner et al. found
that lower ferritin levels were associated with higher
hyperactivity scores in ADHD children, but did not have
a significant influence on cognitive measures [33]. Using
magnetic resonance imaging (MRI) to investigate the as-
sociation of ADHD and brain iron levels in the putamen,
pallidum, caudate, and thalamus, Cortese et al. demon-
strated children with ADHD showed significantly lower
brain iron levels in the right and left thalamus compared
to healthy controls [32]. Other studies, however, did not
find this association between ADHD and the ferritin
level [34,44]. In our study, an increased risk of ADHD
was noted among those with IDA, which was compatible
with a recent meta-analysis result [45]. With regard to
the current pathophysiology of ADHD as involving a
dysfunction of the neurotransmitter systems, IDA sig-
nificantly disturbed the development and functioning of
norepinephrine and dopamine neurotransmitter systems.
Autism spectrum disorder (ASD)
Previous studies have revealed that iron was associated
with socio-cognitive and socio-emotional development
and functioning [46-48]. A disorder in this area is one ofthe core symptoms of ASD. Assessing the prevalence of
ID and IDA among 116 children between 3 and 16 years
old with a diagnosis of ASD, Hergüner et al. revealed
that 24% of patients with ASD had ID, and 15% had IDA
[35]. Latif et al. analyzed the serum ferritin measure-
ments of 96 children with ASD and suggested there was
a high prevalence, up to 30 percent, of ID in children
with ASD [36]. Our result showed an increased risk of
ASD among children and adolescents with IDA,
suggesting a possible reciprocal effect between ASD and
IDA. For example, inappropriate eating habit in those
subjects may be related to IDA and many children with
ASD are picky eaters, which could contribute to IDA.
Furthermore, diffusion-tensor MRI found impaired
white matter integrity and a myelination developmental
abnormality in ASD patients compared to normal sub-
jects [49-51]. Iron was regarded as an essential compo-
nent in myelination and oligodendrogenesis. Myelin
synthesis was limited and altered by ID. Further study
would be needed to clarify the comorbidity or causality
between ASD and IDA.
Unipolar depressive disorder
Numerous studies have reported that IDA was associated
with unipolar depressive disorder, possibly through an al-
teration of the monoamine neurotransmitters by ID
[52-54]. Lower serum ferritin concentrations were signifi-
cantly correlated with depressive symptoms [53,54]. Using
a longitudinal cohort study of 191 participants to evaluate
the association between IDA in infancy and affective and
developmental outcomes in adolescence, Lozoff et al. re-
vealed that those with IDA in infancy exhibited more anx-
iety, depression, social problems, and attentional problems
in later life [40]. Vahdat Shariatpanaahi et al. studied 192
female medical students and found the mean ferritin level
of students with depression was significantly lower than
that of healthy students [53]. Similar results were observed
in a Japanese male population. In a study of 312 men,
those with lower serum ferritin concentration levels had a
higher prevalence of depressive symptoms [54]. Our re-
sult, showing an increased risk of unipolar depressive dis-
order among those with IDA, was compatible with that of
previous studies, and reconfirmed the pathophysiological
association of IDA with unipolar depressive disorder.
Bipolar disorder (BD)
Emotional dysregulation has been deemed as one of the
core neuropsychopathologies of BD [55-57]. It has been
well documented that iron is associated with socio-
emotional development and that ID may disturb the de-
velopment of emotional regulation [40,46,47,58], al-
though clinical studies on the association between IDA
and BD are few. Our results showed a higher prevalence
of BD among IDA subjects. Structural and functional
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the dorsal and ventral prefrontal cortices and the
prefrontal-subcortical and associated limbic circuitry
have been considered as a neuropathology of BD [56,57].
ID has been related to perturbations in myelin forma-
tion, alterations of monoamine neurotransmitter sys-
tems, particularly in the striatum, and deficits in energy
metabolism, particularly in the hippocampus and pre-
frontal cortex [59,60]. The effect of IDA on BD is still
unclear and further study is needed to investigate the
possible causality between IDA and BD. Furthermore, a
significantly increased OR of BD was noted only among
females with IDA after controlling gastrointestinal ulcer,
metrorrhagia, and premenopausal menorrhea. Clarifying
this gender effect between IDA and BD may be needed
in future studies.
Anxiety disorder
Clinical studies on the association between IDA and
anxiety disorder are few. Lozoff et al. found that children
with severe, chronic ID in infancy had a greater preva-
lence of anxiety, depression, and attention problems
[40]. Some animal studies have shown an association be-
tween IDA and alterations in serotonin, norepinephrine,
and gamma-aminobutyric acid (GABA) neurotransmis-
sion [21,61]. In assessing weanling rats with either an
iron deficient diet or a control diet for 6 weeks, Beard
et al. found reduced activity and increased anxiety-like
behaviors among the iron deficient rats with significant
decrements in brain iron content in the corpus striatum,
prefrontal cortex, and midbrain [62]. Emotional
dysregulation due to ID may be a possible mechanism
explaining the association between anxiety and IDA
[63-65]. In our study, both males and females with IDA
had a significantly higher risk of anxiety disorder. How-
ever, establishing causality between IDA and anxiety dis-
order will require further study in the future.
Regarding emotional and cognitive problems, current
neuroanatomical imaging studies have proven that brain
development is a continuous process from infancy to
late adolescence or early adulthood [66,67]. A deficiency
of essential components will greatly impair the normal
trajectory of brain development. Iron is regarded as one
of the essential nutritional elements related to cognitive
and socio-emotional development and functioning. A
significantly higher risk of anxiety disorder, ASD, ADHD,
delayed development, and mental retardation was noted
among children (below age 13) with IDA. After entering
adolescence (age 13 ~ 18), those with IDA had an in-
creased risk of unipolar depressive disorder, BD, anxiety
disorder, ADHD, delayed development, and mental re-
tardation. These results may indicate that ID, whether in
childhood or adolescence, does have a great impact on
psychiatric comorbidities. Moreover, iron deletion inchildhood has immediate and chronic effects on brain
development, in that children with IDA exhibited an in-
creased risk of delayed development and mental retard-
ation with persistent sequelae of cognitive impairment
and emotional problems during adolescence.
Tic disorder
We found a significantly increased risk of tic disorder
among females with IDA. The association between IDA
and tic disorder is unclear and rarely reported in the lit-
erature. Cortese et al. mentioned a possible iron hypoth-
esis in a possible spectrum disorder of ADHD, restless
leg syndrome, and tic disorder, because these 3 disorders
were sometimes comorbid and shared a pathogenesis
similar to monoamine neurotransmitter dysfunction
[68]. Exploring the associations of ferritin levels with re-
gional brain volumes among patients with Tourette’s
syndrome, Gorman et al. demonstrated ferritin and
serum iron levels were significantly lower in the
Tourette's syndrome subjects and that ferritin correlated
positively with putamen volume [69]. Combining these
results with ours may inspire further study to clarify the
effect of iron on tic disorder or other movement disor-
ders, especially in female populations.
Some limitations in our study should be mentioned
here. First, the prevalence of psychiatric disorders was
deemed underestimated because our results were de-
rived from insurance registry-based data. Only those in-
dividuals who used the medical resource to seek
psychiatric help were identified. However, patients in-
cluded in our study were given a diagnosis by board-
certified physicians and the diagnoses were more reliable
than self-reported ones. Second, those subjects who
were not diagnosed as having IDA ever but had iron de-
ficiency problem cannot be detected in our study. The
clinical study would be required to elucidate the possible
association between psychiatric disorders and iron defi-
ciency or subthreshold IDA. Third, ID may be due to in-
appropriate eating habits in some cases but the
association among IDA, eating disorder, and episodic
mood disorder with changed eating pattern is still un-
clear. In our study, we focused on the risks of psychiatric
comorbidities in patients with IDA and the further study
is required to analyze the effect of inappropriate eating
pattern of specific psychiatric disorder on the risk of
IDA. Fourth, we had no personal information that could
contribute to an understanding of the risk of psychiatric
disorders in patients, such as environmental factors (i.e.
long-term life stress, traumatic experience), and family
history of psychiatric disorder. Forth, the causality be-
tween IDA and psychiatric disorders cannot be proved
in our study, even though our results did indicate a sig-
nificant association between IDA and psychiatric
disorders.
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In conclusion, patients with IDA did have a higher risk
of psychiatric disorders, including unipolar depressive
disorder, BD, anxiety disorder, ASD, ADHD, delayed de-
velopment, and mental retardation. When encountering
patients with IDA in clinical practice, prompt iron sup-
plementation should be considered to prevent possible
psychiatric sequelae, because ID does impair the devel-
opment of emotional regulation and cognition. And vice
versa, psychiatrists should check the iron level in those
children and adolescents with psychiatric disorders. Fi-
nally, further well-designed cohort studies are needed to
elucidate the causality or comorbid effect between IDA
and psychiatric disorders.
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